-+ 0.00%
-+ 0.00%
-+ 0.00%

CytoDyn Names Robert E. Hoffman CEO, Succeeding Jacob Lalezari

PUBT·10/19/2026 20:52:11
Diffusion vocale
CytoDyn Names Robert E. Hoffman CEO, Succeeding Jacob Lalezari
  • CytoDyn appointed principal accounting officer Robert E. Hoffman CEO, effective Oct. 20, 2026, replacing Jacob Lalezari.
  • Lalezari, CEO since November 2023, will become head of research and translational sciences, focusing on new solid-tumor oncology opportunities for leronlimab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191650PRIMZONEFULLFEED9848643) on October 19, 2026, and is solely responsible for the information contained therein.